Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer

Fu, Ting; Chan, Tracey W.; Bahn, Jae Hoon; Kim, Tae-Hyung; Rowat, Amy C.; Xiao, Xinshu

doi:10.1016/j.isci.2022.104836

Cited by 2 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to what extent this process affects transformation has not been deeply elucidated yet. Recently, it was shown that editing of the PODXL pre-mRNA promotes the inclusion of an alternative exon [82]. The resulting edited PODXL long isoform is more prone to protease digestion and reducing cell migration and cisplatin chemoresistance [82].…”

Section: Dysregulation Of Rna Editing In Cancer Progressionmentioning

confidence: 99%

See 1 more Smart Citation

RNA Editing in Cancer Progression

Frezza,

Chellini,

Del Verme

et al. 2023

Cancers

View full text Add to dashboard Cite

Coding and noncoding RNA molecules play their roles in ensuring cell function and tissue homeostasis in an ordered and systematic fashion. RNA chemical modifications can occur both at bases and ribose sugar, and, similarly to DNA and histone modifications, can be written, erased, and recognized by the corresponding enzymes, thus modulating RNA activities and fine-tuning gene expression programs. RNA editing is one of the most prevalent and abundant forms of post-transcriptional RNA modification in normal physiological processes. By altering the sequences of mRNAs, it makes them different from the corresponding genomic template. Hence, edited mRNAs can produce protein isoforms that are functionally different from the corresponding genome-encoded variants. Abnormalities in regulatory enzymes and changes in RNA-modification patterns are closely associated with the occurrence and development of various human diseases, including cancer. To date, the roles played by RNA modifications in cancer are gathering increasing interest. In this review, we focus on the role of RNA editing in cancer transformation and provide a new perspective on its impact on tumorigenesis, by regulating cell proliferation, differentiation, invasion, migration, stemness, metabolism, and drug resistance.

show abstract

Section: Dysregulation Of Rna Editing In Cancer Progressionmentioning

confidence: 99%

“…Remarkably, the editing level of the PODXL transcript and the inclusion level of the PODXL alternative exon were strongly associated with overall patient survival in kidney renal clear cell carcinoma (KIRC) [82].…”

Section: Dysregulation Of Rna Editing In Cancer Progressionmentioning

confidence: 99%

RNA Editing in Cancer Progression

Frezza,

Chellini,

Del Verme

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

ADAR-Mediated A>I(G) RNA Editing in the Genotoxic Drug Response of Breast Cancer

Bernal,

Durán,

Solar

et al. 2024

IJMS

View full text Add to dashboard Cite

Epitranscriptomics is a field that delves into post-transcriptional changes. Among these modifications, the conversion of adenosine to inosine, traduced as guanosine (A>I(G)), is one of the known RNA-editing mechanisms, catalyzed by ADARs. This type of RNA editing is the most common type of editing in mammals and contributes to biological diversity. Disruption in the A>I(G) RNA-editing balance has been linked to diseases, including several types of cancer. Drug resistance in patients with cancer represents a significant public health concern, contributing to increased mortality rates resulting from therapy non-responsiveness and disease progression, representing the greatest challenge for researchers in this field. The A>I(G) RNA editing is involved in several mechanisms over the immunotherapy and genotoxic drug response and drug resistance. This review investigates the relationship between ADAR1 and specific A>I(G) RNA-edited sites, focusing particularly on breast cancer, and the impact of these sites on DNA damage repair and the immune response over anti-cancer therapy. We address the underlying mechanisms, bioinformatics, and in vitro strategies for the identification and validation of A>I(G) RNA-edited sites. We gathered databases related to A>I(G) RNA editing and cancer and discussed the potential clinical and research implications of understanding A>I(G) RNA-editing patterns. Understanding the intricate role of ADAR1-mediated A>I(G) RNA editing in breast cancer holds significant promise for the development of personalized treatment approaches tailored to individual patients’ A>I(G) RNA-editing profiles.

show abstract

Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer

Cited by 2 publications

References 80 publications

RNA Editing in Cancer Progression

RNA Editing in Cancer Progression

ADAR-Mediated A>I(G) RNA Editing in the Genotoxic Drug Response of Breast Cancer

Contact Info

Product

Resources

About